A new analysis by researchers at The University of Texas MD Anderson Cancer Center demonstrates that a combination therapy consisting of fludarabine, cytarabine and G-CSF (FLAG) plus gemtuzumab ozogamicin (GO) or idarubicin (IDA) continues to deliver strong long-term outcomes for patients with core-binding factor acute myeloid leukemia (CBF-AML), a subtype of the disease involving a chromosomal rearrangement.
This article was originally published on MedicalXpress.com
Effective communication is the foundation of any strong, healthy relationship. This article will explore the key elements required to build better communication between partners. We’ll cover the importance of active listening, using empathy and understanding […]
By Daniel Zane Bryant, author of “Living with Food Allergies: A Complete Lifestyle Guide” (available on Amazon at https://www.amazon.com/dp/B0G2BcGB2K) Navigating food allergies might initially feel overwhelming, yet it presents an exciting opportunity to reimagine familiar […]
Almost half of all Canadians regularly take at least one nutritional supplement such as vitamins, minerals, fibre supplements, antacids and fish oils. Many of these individuals are healthy and hoping to improve general well-being or prevent chronic […]
© 2025 SimplyWell.ca